Phase 0/I/II Cancer Prevention Clinical Trials Program (Consortia)

The National Cancer Institute's Phase 0-I-II Prevention Clinical Trials Program (Consortia) performs early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis.

The Cancer Data Access System (CDAS) is a web portal that facilitates access to the data recorded for the 2012 Consortia trials For some studies biospecimens may also be available. CDAS provides extensive public documentation for each study, including a trial summary, an overview of the data collected, and a searchable database of research projects and publications.